MCID: MCR161
MIFTS: 30

Macroglobulinemia, Waldenstrom 1

Categories: Genetic diseases, Rare diseases, Neuronal diseases, Blood diseases, Immune diseases

Aliases & Classifications for Macroglobulinemia, Waldenstrom 1

MalaCards integrated aliases for Macroglobulinemia, Waldenstrom 1:

Name: Macroglobulinemia, Waldenstrom 1 54
Macroglobulinemia, Waldenstrom, Somatic 54 29
Macroglobulinemia, Waldenstrom, Susceptibility to, 1 13
Macroglobulinemia, Waldenstrom Somatic 24

Characteristics:

OMIM:

54
Inheritance:
autosomal dominant


HPO:

32
macroglobulinemia, waldenstrom 1:
Inheritance autosomal dominant inheritance


Classifications:



Summaries for Macroglobulinemia, Waldenstrom 1

OMIM : 54
Waldenstrom macroglobulinemia (WM) is a malignant B-cell neoplasm characterized by lymphoplasmacytic infiltration of the bone marrow and hypersecretion of monoclonal immunoglobulin M (IgM) protein (review by Vijay and Gertz, 2007). The importance of genetic factors is suggested by the observation of familial clustering of WM (McMaster, 2003). Whereas WM is rare, an asymptomatic elevation of monoclonal IgM protein, termed 'IgM monoclonal gammopathy of undetermined significance' (IgM MGUS) is more common. Patients with IgM MGUS can progress to develop WM, at the rate of 1.5% to 2% per year (Kyle et al., 2003). (153600)

MalaCards based summary : Macroglobulinemia, Waldenstrom 1, also known as macroglobulinemia, waldenstrom, somatic, is related to major depressive disorder and accelerated response to antidepressant drug treatment, and has symptoms including leukemia, lymphoma and polyneuropathy. An important gene associated with Macroglobulinemia, Waldenstrom 1 is MYD88 (Myeloid Differentiation Primary Response 88). The drugs rituximab and Bortezomib have been mentioned in the context of this disorder. Affiliated tissues include b cells, bone and bone marrow.

Related Diseases for Macroglobulinemia, Waldenstrom 1

Diseases in the Waldenstrom Macroglobulinemia family:

Macroglobulinemia, Waldenstrom 2 Macroglobulinemia, Waldenstrom 1

Diseases related to Macroglobulinemia, Waldenstrom 1 via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 major depressive disorder and accelerated response to antidepressant drug treatment 9.5 MYD88 WM1

Symptoms & Phenotypes for Macroglobulinemia, Waldenstrom 1

Symptoms via clinical synopsis from OMIM:

54

Neuro:
polyneuropathy

Heme:
waldenstrom macroglobulinemia

Lab:
impaired lymphocyte transformation with phytohemagglutinin
polyclonal elevation of igm

Oncology:
increased frequency of lymphoma, leukemia, and adenocarcinom of lung


Clinical features from OMIM:

153600

Human phenotypes related to Macroglobulinemia, Waldenstrom 1:

32 (show all 6)
id Description HPO Frequency HPO Source Accession
1 leukemia 32 occasional (7.5%) HP:0001909
2 lymphoma 32 occasional (7.5%) HP:0002665
3 polyneuropathy 32 HP:0001271
4 impaired lymphocyte transformation with phytohemagglutinin 32 HP:0003347
5 polyclonal elevation of igm 32 HP:0003459
6 monoclonal immunoglobulin m proteinemia 32 HP:0005508

Drugs & Therapeutics for Macroglobulinemia, Waldenstrom 1

Drugs for Macroglobulinemia, Waldenstrom 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 207)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
rituximab Approved Phase 3,Phase 2,Phase 1,Early Phase 1 174722-31-7 10201696
2
Bortezomib Approved, Investigational Phase 3,Phase 2,Phase 1 179324-69-7 387447 93860
3
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
4
Chlorambucil Approved Phase 3 305-03-3 2708
5
Fludarabine Approved Phase 3,Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
6
Vidarabine Approved Phase 3,Phase 2,Phase 1 24356-66-9 32326 21704
7
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
8
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
9
Prednisone Approved, Vet_approved Phase 3,Phase 2,Phase 1,Early Phase 1 53-03-2 5865
10
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
11
Idelalisib Approved Phase 3,Phase 2,Phase 1 870281-82-6
12
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
13 Alkylating Agents Phase 3,Phase 1,Phase 2,Early Phase 1
14 Anti-Infective Agents Phase 3,Phase 1,Phase 2
15 Antimetabolites Phase 3,Phase 1,Phase 2
16 Antimetabolites, Antineoplastic Phase 3,Phase 1,Phase 2
17 Antiviral Agents Phase 3,Phase 1,Phase 2
18 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Early Phase 1
19 Anti-Bacterial Agents Phase 3,Phase 1,Phase 2
20 Anti-Inflammatory Agents Phase 3,Phase 2,Phase 1,Early Phase 1
21 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Phase 1,Early Phase 1
22 Antineoplastic Agents, Phytogenic Phase 3,Phase 1,Phase 2,Early Phase 1
23 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Early Phase 1
24 glucocorticoids Phase 3,Phase 2,Phase 1,Early Phase 1
25 Hormone Antagonists Phase 3,Phase 2,Phase 1,Early Phase 1
26 Hormones Phase 3,Phase 2,Phase 1,Early Phase 1
27 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1,Early Phase 1
28 Topoisomerase Inhibitors Phase 3,Phase 1,Phase 2,Early Phase 1
29 Antiemetics Phase 3,Phase 2,Phase 1
30 Autonomic Agents Phase 3,Phase 2,Phase 1
31 BB 1101 Phase 3,Phase 2,Phase 1
32 Dexamethasone acetate Phase 3,Phase 2,Phase 1 1177-87-3
33 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
34 HIV Protease Inhibitors Phase 3,Phase 2,Phase 1
35 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
36
protease inhibitors Phase 3,Phase 2,Phase 1
37 Antibiotics, Antitubercular Phase 3,Phase 1,Phase 2
38 Antimitotic Agents Phase 3,Phase 2,Phase 1
39 Bendamustine Hydrochloride Phase 3,Phase 1,Phase 2
40 tyrosine Nutraceutical Phase 3,Phase 1,Phase 2
41
belimumab Approved Phase 2 356547-88-1 5957 10451420
42
Cysteamine Approved, Investigational Phase 1, Phase 2 60-23-1 6058
43
Carmustine Approved Phase 1, Phase 2 154-93-8 2578
44
Cytarabine Approved, Investigational Phase 1, Phase 2 147-94-4 6253
45
Etoposide Approved Phase 1, Phase 2, Early Phase 1 33419-42-0 36462
46
Lenalidomide Approved Phase 1, Phase 2 191732-72-6 216326
47
Mechlorethamine Approved Phase 1, Phase 2 51-75-2 4033
48
Melphalan Approved Phase 1, Phase 2 148-82-3 4053 460612
49
alemtuzumab Approved, Investigational Phase 2,Phase 1 216503-57-0
50
Levoleucovorin Approved Phase 1, Phase 2 68538-85-2

Interventional clinical trials:

(show top 50) (show all 188)

id Name Status NCT ID Phase Drugs
1 Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia Completed NCT00566332 Phase 3 Chlorambucil;Fludarabine
2 Chlorambucil or Fludarabine as First-Line Therapy in Treating Patients With Previously Untreated Waldenström Macroglobulinemia, Splenic Lymphoma, or Lymphoplasmacytic Lymphoma Completed NCT00608374 Phase 3 chlorambucil;fludarabine phosphate
3 First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. Completed NCT00801281 Phase 3 Rituximab;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone 1;Prednisone 2
4 A Study Comparing BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM) Recruiting NCT03053440 Phase 3 BGB-3111;Ibrutinib
5 Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia Recruiting NCT01788020 Phase 3 Dexamethasone, Rituximab, Cyclophosphamide;Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib
6 Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers Recruiting NCT02991638 Phase 3 Ibrutinib
7 Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia Active, not recruiting NCT02165397 Phase 3 Ibrutinib;Placebo;Rituximab
8 A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneo Active, not recruiting NCT01461928 Phase 3 Chemotherapy (Induction Period);Rituximab
9 Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Terminated NCT01732926 Phase 3 Idelalisib;Rituximab;Bendamustine;Placebo
10 Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Terminated NCT01732913 Phase 3 Placebo;Rituximab;Idelalisib
11 Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia Unknown status NCT00003512 Phase 2 antineoplaston A10;antineoplaston AS2-1
12 Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia Unknown status NCT01046006 Phase 2 Bortezomib, Rituximab, Dexamethasone
13 A Study of Belimumab in Treating Symptomatic Waldenstroms Macroglobulinaemia Unknown status NCT01142011 Phase 2 Belimumab
14 A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531 Unknown status NCT01813227 Phase 2 Carfilzomib;Rituximab;Dexamethasone
15 Beta Alethine in Treating Patients With Waldenstrom's Macroglobulinemia Unknown status NCT00041379 Phase 1, Phase 2 beta alethine
16 Lenalidomide as Maintenance Therapy After Combination Chemotherapy With or Without Rituximab and Stem Cell Transplant in Treating Patients With Persistent or Recurrent Non-Hodgkin Lymphoma That is Resistant to Chemotherapy Unknown status NCT01035463 Phase 1, Phase 2 lenalidomide;carmustine;etoposide;cytarabine;melphalan
17 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
18 Phase II Study of Campath-1H Antibody to Treat Waldenstrom's Macroglobulinemia Completed NCT00142181 Phase 2 Campath-1H
19 A Study for Patients That Have Been Previously Been Treated in Waldenstrom's Macroglobulinemia or Multiple Myeloma Completed NCT00718419 Phase 2 Enzastaurin
20 A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia Completed NCT00811733 Phase 2
21 Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia Completed NCT02302469 Phase 1, Phase 2 Revlimid
22 Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia Completed NCT00062244 Phase 1, Phase 2
23 Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia Completed NCT00004889 Phase 2
24 Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia Completed NCT00250926 Phase 2 Bortezomib;Dexamethasone;Rituximab
25 Efficacy of Bortezomib (Velcade(R)) in Patients With Advanced Waldenström Macroglobulinemia Completed NCT00777738 Phase 2 BORTEZOMIB
26 Extension Study of IMO-8400 in Patients With Waldenström's Macroglobulinemia Who Completed Study 8400-401 Completed NCT02363439 Phase 1, Phase 2 IMO-8400
27 Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Low-Grade Non-Hodgkin Lymphoma Completed NCT00784927 Phase 2 cyclophosphamide;dexamethasone;lenalidomide
28 Radiolabeled Monoclonal Antibody Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Lymphoma or Waldenstrom's Macroglobulinemia Completed NCT00004107 Phase 1, Phase 2
29 S9805, High-Dose Melphalan Plus Peripheral Stem Cell Transplantation Followed by Interferon Alfa in Treating Patients With Waldenstrom's Macroglobulinemia Completed NCT00003416 Phase 2 dexamethasone;melphalan
30 Bortezomib, Dexamethasone, and Rituximab in Untreated Waldenstroms Macroglobulinemia Completed NCT00832234 Phase 2 Bortezomib, Dexamethasone, Rituximab
31 Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia Completed NCT01470196 Phase 2 Dexamethasone;Carfilzomib;Rituximab
32 Imexon for Relapsed Follicular and Aggressive Lymphomas Completed NCT01314014 Phase 2 Imexon
33 Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies Completed NCT00481871 Phase 1, Phase 2 Pralatrexate Injection;Gemcitabine Hydrochloride
34 Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies Completed NCT00536978 Phase 2 ARA-C;BCNU;Campath-1H;Cyclophosphamide;Etoposide;Fludarabine;Melphalan;Rituximab;Methotrexate;Tacrolimus
35 Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Completed NCT01474681 Phase 1, Phase 2
36 Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan Completed NCT00496873 Phase 2 Cytoxan;Nipent;Rituxan
37 Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia Completed NCT00281983 Phase 1, Phase 2 busulfan;cyclophosphamide;cyclosporine;fludarabine phosphate;methotrexate;mycophenolate mofetil
38 Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL Completed NCT00546793 Phase 1, Phase 2
39 Dolastatin 10 in Treating Patients With Indolent Lymphoma, Waldenstrom's Macroglobulinemia, or Chronic Lymphocytic Leukemia Completed NCT00005579 Phase 2 dolastatin 10
40 Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma Completed NCT00058240 Phase 1, Phase 2 alvocidib
41 Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors Completed NCT01326702 Phase 1, Phase 2 Bendamustine Hydrochloride;Veliparib
42 Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies Completed NCT01273766 Phase 2 deferasirox
43 Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Completed NCT00006473 Phase 2 oxaliplatin
44 Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Completed NCT00601718 Phase 1, Phase 2 vorinostat;ifosfamide;carboplatin;etoposide
45 Bryostatin 1 and Rituximab in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Completed NCT00087425 Phase 2 bryostatin 1
46 Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder Completed NCT00064246 Phase 1, Phase 2
47 Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies Completed NCT01744912 Phase 1, Phase 2 Ublituximab;Lenalidomide
48 Safety, PK, PD, and Antitumor Activity of SNS-062 in B Lymphoid Cancers Recruiting NCT03037645 Phase 1, Phase 2 SNS-062
49 Fase II Study With BRB for Non-Hodgkin Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia's Recruiting NCT02371148 Phase 2 Bortezomib-Rituximab-Bendamustine
50 Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas Recruiting NCT02332980 Phase 2 Ibrutinib;Idelalisib

Search NIH Clinical Center for Macroglobulinemia, Waldenstrom 1

Genetic Tests for Macroglobulinemia, Waldenstrom 1

Genetic tests related to Macroglobulinemia, Waldenstrom 1:

id Genetic test Affiliating Genes
1 Macroglobulinemia, Waldenstrom, Somatic 29
2 Macroglobulinemia, Waldenstrom Somatic 24 MYD88

Anatomical Context for Macroglobulinemia, Waldenstrom 1

MalaCards organs/tissues related to Macroglobulinemia, Waldenstrom 1:

39
B Cells, Bone, Bone Marrow, Liver, Kidney, T Cells, Nk Cells

Publications for Macroglobulinemia, Waldenstrom 1

Variations for Macroglobulinemia, Waldenstrom 1

ClinVar genetic disease variations for Macroglobulinemia, Waldenstrom 1:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 MYD88 NM_001172567.1(MYD88): c.818T> C (p.Leu273Pro) single nucleotide variant Pathogenic/Likely pathogenic rs387907272 GRCh37 Chromosome 3, 38182641: 38182641

Expression for Macroglobulinemia, Waldenstrom 1

Search GEO for disease gene expression data for Macroglobulinemia, Waldenstrom 1.

Pathways for Macroglobulinemia, Waldenstrom 1

GO Terms for Macroglobulinemia, Waldenstrom 1

Sources for Macroglobulinemia, Waldenstrom 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....